Abstract 1593P
Background
Adolescent and young adults (AYA) with underlying cancer often experience multiple General Practitioner (GP) consultations before they are referred to a specialist. Certain patient groups may be at higher risk of such events, but evidence is lacking, particularly from Australia. We aimed to examine GP activity prior to cancer diagnosis in an Australian cohort of AYAs and factors associated with multiple GP consultations.
Methods
We conducted an Australian cohort study of patients aged 18–39 years with incident cancer recorded in the Victorian Cancer Registry between 2008-2022 and linkage to the Patron primary care dataset. We calculated the frequency of GP events in the year before cancer diagnosis (GP consultations, prescriptions, blood test and imaging) and the proportion of patients with multiple GP consultations (≥4) in this period. Using multivariable logistic regression models, we examined associations between multiple pre-diagnostic GP consultations and patient characteristics, including age, sex, socioeconomic status, regional or city location, culturally and linguistically diverse background and main spoken language.
Results
1,712 AYAs with cancer were identified: 276 aged 18–25 and 1,436 aged 26–39. AYAs had a mean of 3 GP consults in the six months pre-diagnosis (range 0-46), with 1,035 (60%) AYAs having a GP consultation in this period and 434 AYAs (25%) consulting a GP 4 or more times. AYAs living in regional Australia were more likely to have 4 or more consultations (adjusted odds ratio (AOR) 1.67, 95%CI 1.32-2.10, p<0.001) as were those diagnosed in more recent years, particularly between 2020-2022 (AOR 1.54, 95%CI 1.14-2.07, p=0.005). In AYAs aged 18-25 years, the most deprived patients were more likely to have multiple GP consults (AOR 3.46, 95%CI 1.55-7.72, p=0.002), with no evidence of an association was observed in AYAs aged 26-40.
Conclusions
Our findings identify AYA patient groups at higher risk of multiple GP consultations before cancer diagnosis and at risk of having a prolonged diagnostic journey. These findings could help to inform policy and prioritise early diagnosis interventions focusing on these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Melbourne Human Ethics team in the Office of Research Ethics and Integrity.
Funding
Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10